Liquid biopsy in ovarian cancer:Catching the silent killer before it strikes  

作　　者：Laura Feeney Ian JG Harley W Glenn McCluggage Paul B Mullan James P Beirne 

机构地区：[1]Patrick G Johnston Centre for Cancer Research,Queens University,Belfast BT97AE,United Kingdom [2]Northern Ireland Gynaecological Cancer Centre,Belfast Health and Social Care Trust,Belfast BT97AB,United Kingdom [3]Department of Pathology,Belfast Health and Social Care Trust,Belfast BT126BL,United Kingdom [4]Trinity St James Cancer Institute,St.James’Hospital,Dublin 8,Ireland

出　　处：《World Journal of Clinical Oncology》2020年第11期868-889,I0002,共23页世界临床肿瘤学杂志（英文版）

摘　　要：Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy in the western world.The majority of women presenting with the disease are asymptomatic and it has been dubbed the“silent killer”.To date there is no effective minimally invasive method of stratifying those with the disease or screening for the disease in the general population.Recent molecular and pathological discoveries,along with the advancement of scientific technology,means there is a real possibility of having disease-specific liquid biopsies available within the clinical environment in the near future.In this review we discuss these discoveries,particularly in relation to the most common and aggressive form of EOC,and their role in making this possibility a reality.

关 键 词：Epithelial ovarian cancer Molecular profile Liquid biopsy Circulating tumor DNA Biomarker discovery Precision medicine 

分 类 号：R737.31[医药卫生—肿瘤]